Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
, Zentrum für Innere Medizin
Aktuelle Veranstaltungen
-
WiSe 2025
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
-
SoSe 2024
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment : an intraindividual analysis by the German Study Group for MPN (GSG-MPN)In: Leukemia, Jg. 39, 2025, Nr. 4, S. 864 – 875DOI (Open Access)
-
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment : Results of the prospective PONS trialIn: Acta Haematologica, 2025, in press
-
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) : practical approaches of a German expert panel discussion in 2024In: Annals of Hematology, Jg. 104, 2025, Nr. 1, S. 295 – 306DOI (Open Access)
-
Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms : Implications from the GSG-MPN bioregistryIn: HemaSphere: Open Access Journal of the European Hematology Association, Jg. 9, 2025, Nr. 3, e70090DOI (Open Access)
-
Endothelial eNOS deficiency causes podocyte injury through NFAT2 and heparanase in diabetic miceIn: Scientific Reports, Jg. 14, 2024, Nr. 1, 29179DOI (Open Access)
-
Myelofibrosis and anemia : A German claims data analysis to describe epidemiology and current treatmentIn: European Journal of Haematology, Jg. 113, 2024, Nr. 5, S. 704 – 715DOI (Open Access)
-
Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategiesIn: Blood Cancer Discovery, Jg. 4, 2023, Nr. 1, S. 78 – 97DOI (Open Access)
-
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy : results of the Bosutinib Dose Optimization (BODO) StudyIn: Annals of Hematology, Jg. 102, 2023, Nr. 10, S. 2741 – 2752DOI (Open Access)
-
Pattern of tamoxifen-induced Tie2 deletion in endothelial cells in mature blood vessels using endo SCL-Cre-ERT transgenic miceIn: PLoS ONE, Jg. 17, 2022, Nr. 6, e0268986DOI (Open Access)
-
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyIn: Leukemia, Jg. 35, 2021, Nr. 3, S. 701 – 711DOI (Open Access)
-
Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms : Implications from the german study group for mpn bioregistryIn: Cancers, Jg. 13, 2021, Nr. 16, 4086DOI (Open Access)
-
Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe diseaseIn: Nature Communications, Jg. 11, 2020, Nr. 1, S. 1338DOI, Online Volltext (Open Access)
-
Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinibIn: BMC Cancer, Jg. 20, 2020, Nr. 1, 650DOI (Open Access)
-
Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2In: Cellular Physiology and Biochemistry, Jg. 54, 2020, Nr. 4, S. 767 – 790DOI (Open Access)
-
Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AMLIn: Journal of Hematology and Oncology, Jg. 12, 2019, Nr. 1, S. 72DOI (Open Access)
-
CEACAM1 promotes CD8⁺ T cell responses and improves control of a chronic viral infectionIn: Nature Communications, Jg. 9, 2018, 2561DOI (Open Access)
-
Expansion of functional personalized cells with specific transgene combinations.In: Nature Communications, Jg. 9, 2018, Nr. 1, S. 994DOI (Open Access)
-
Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau diseaseIn: Blood, Jg. 132, 2018, Nr. 5, S. 469 – 483DOI (Open Access)
-
Pathological manifestations of Farber disease in a new mouse modelIn: Biological Chemistry, Jg. 399, 2018, Nr. 10, S. 1183 – 1202DOI, Online Volltext (Open Access)
-
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemiaIn: OncoTarget, Jg. 9, 2018, Nr. 41, S. 26353 – 26369DOI (Open Access)
-
Growth factor independence 1 (GFI !) regulates the AML supporting function of mesenchymal stromal cellsIn: Haematologica / The Hematology Journal, Jg. 102, 2017, Nr. Suppl. 2, S. 459 – 459
-
Identification and characterization of a dendritic cell precursor in parenchymal lung tissueIn: American Journal of Respiratory Cell and Molecular Biology, Jg. 56, 2017, Nr. 3, S. 353 – 361
-
Identification of cardiac hemo-vascular precursors and their requirement of sphingosine-1-phosphate receptor 1 for heart developmentIn: Scientific Reports, Jg. 7, 2017, S. 45205DOI (Open Access)
-
Regulation of Arthritis Severity by the Acid SphingomyelinaseIn: Cellular Physiology and Biochemistry, Jg. 43, 2017, Nr. 4, S. 1460 – 1471DOI (Open Access)
-
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN) : analysis from the German SAL-MPN-registryIn: Journal of Hematology and Oncology, Jg. 9, 2016, 18DOI (Open Access)
-
Deorphanization and characterization of the ectopically expressed olfactory receptor OR51B5 in myelogenous leukemia cellsIn: Cell Death Discovery, Jg. 2, 2016, Nr. 1, 16010DOI (Open Access)
-
Endothelial β-Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and Central Nervous System HomeostasisIn: Circulation, Jg. 133, 2016, Nr. 2, S. 177 – 186DOI, Online Volltext (Open Access)
-
Functional characterization of the ectopically expressed olfactory receptor 2AT4 in human myelogenous leukemiaIn: Cell Death Discovery, Jg. 2, 2016, 15070DOI (Open Access)
-
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN) : a comparison between university hospitals, community hospitals, and office-based physiciansIn: Annals of Hematology, Jg. 95, 2016, Nr. 9, S. 1399 – 1410
-
Hemovascular Progenitors in the Kidney Require Sphingosine-1-Phosphate Receptor 1 for Vascular DevelopmentIn: Journal of the American Society of Nephrology (JASN), Jg. 27, 2016, Nr. 7, S. 1984 – 1995DOI (Open Access)
-
Smoking associated secondary erythrocytosis by chronic carbon monoxide poisoningIn: Tägliche Praxis, Jg. 57, 2016, Nr. 1, S. 33 – 37
-
The bulk of the hematopoietic stem cell population is dispensable for murine steady-state and stress hematopoiesisIn: Experimental Hematology, Jg. 44, 2016, Nr. 9 Suppl., S. S97
-
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative NeoplasmIn: Medicine, Jg. 95, 2016, Nr. 20, S. e3355DOI (Open Access)
-
CEACAM1 induces B-cell survival and is essential for protective antiviral antibody productionIn: Nature Communications, Jg. 6, 2015, 6217DOI (Open Access)
-
Catchup : a mouse model for imaging-based tracking and modulation of neutrophil granulocytesIn: Nature Methods, Jg. 12, 2015, Nr. 5, S. 445 – 452
-
Deficiency in lymphotoxin β receptor protects from atherosclerosis in apoE-deficient miceIn: Circulation Research, Jg. 116, 2015, Nr. 8, S. e57 – e68DOI (Open Access)
-
Long-term-repopulating hematopoietic stem cells are dispensable in steady state but essential for stress hematopoiesisIn: Experimental Hematology, Jg. 43, 2015, Nr. 9 Suppl., S. 94
-
Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectinIn: Nature Communications, Jg. 6, 2015, S. 6416DOI (Open Access)
-
Exacerbation of ischemic brain injury in hypercholesterolemic mice is associated with pronounced changes in peripheral and cerebral immune responsesIn: Neurobiology of Disease, Jg. 62, 2014, S. 456 – 468
-
Reduction of atherosclerosis and macrophage infiltration in apoe/lymphotoxin beta-receptor double-deficient miceIn: Atherosclerosis, 2014
-
Involvement of Toso in activation of monocytes, macrophages, and granulocytesIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS), Jg. 110, 2013, Nr. 7, S. 2593 – 2598
-
Knock-down of lysine specific demethylase-1 drives hematopoietic stem cells into a CD41+myeloid biased phenotypeIn: Onkologie, Jg. 36, 2013, Nr. Suppl. 7, S. 228 – 228
-
Loss of TLR2 worsens spontaneous colitis in MDR1A deficiency through commensally induced pyroptosisIn: The Journal of Immunology (JI), Jg. 190, 2013, Nr. 11, S. 5676 – 5688
-
Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilizationIn: Journal of Experimental Medicine (JEM), Jg. 210, 2013, Nr. 11, S. 2337 – 2349DOI (Open Access)
-
Selective involvement of serum response factor in pressure-induced myogenic tone in resistance arteriesIn: Arteriosclerosis, Thrombosis, and Vascular Biology, Jg. 33, 2013, Nr. 2, S. 339 – 346
-
Genetic modification of the oxygen-sensing pathway alters the develoment of early thymic progenitorsIn: Experimental Hematology, Jg. 40, 2012, Nr. 8, Suppl. 1, S. 21 – 22
-
Immunomodulatory activity in the supernatants of novel human bone marrow stroma cell lines from a normal donor and leukemia patientsIn: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 120 – 121
-
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiationIn: Leukemia, Jg. 26, 2012, Nr. 9, S. 2039 – 2051
-
Maßgeschneiderte Nager : Genetisch veränderte Mäuse helfen bei der Entwicklung zielgerichteter TherapienIn: Unikate: Berichte aus Forschung und Lehre, 2012, Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 42 – 50DOI, Online Volltext (Open Access)
-
Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMPIn: The FASEB Journal, Jg. 26, 2012, Nr. 2, S. 523 – 532
-
A Novel Mechanism Involved in the Pathogenesis of Graves Ophthalmopathy (GO) : Clathrin Is a Possible Targeting Molecule for Inhibiting Local Immune Response in the OrbitIn: The Journal of Clinical Endocrinology & Metabolism (JCEM), Jg. 96, 2011, Nr. 11, S. E1727 – 1736
-
Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft modelIn: European Journal of Haematology, Jg. 87, 2011, Nr. 1, S. 10 – 19
-
Novel human bone marrow stroma cell lines from a normal donor and leukemia and lymphoma patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie, Jg. 34, 2011, Nr. Suppl. 6, S. 260 -
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cellsIn: Blood, Jg. 115, 2010, Nr. 16, S. 3185 – 3195
-
Lipopolysaccharide evokes resistance to erythropoiesis induced by the long-acting erythropoietin analogue darbepoetin alfa in ratsIn: Anesthesia & analgesia, Jg. 109, 2009, Nr. 3, S. 705 – 711
-
Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAKIn: The Journal of Cell Biology (JCB), Jg. 181, 2008, Nr. 1, S. 43 – 50
-
Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factorIn: Blood, Jg. 111, 2008, Nr. 5, S. 2674 – 2680
-
A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the diseaseIn: Cancer Research, Jg. 67, 2007, Nr. 18, S. 8653 – 8661
-
NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesisIn: Blood, Jg. 110, 2007, Nr. 10, S. 3753 – 3762
-
Temporal regulation of Cre-recombinase activity in Scl-positive neurons of the central nervous systemIn: Genesis : the journal of genetics and development, Jg. 45, 2007, Nr. 3, S. 145 – 151
-
The essential haematopoietic transcription factor Scl is also critical for neuronal developmentIn: European journal of neuroscience : EJN, Jg. 23, 2006, Nr. 7, S. 1677 – 1689
-
In vivo fate-tracing studies using the Scl stem cell enhancer : embryonic hematopoietic stem cells significantly contribute to adult hematopoiesisIn: Blood, Jg. 105, 2005, Nr. 7, S. 2724 – 2732
-
Genetically tagging endothelial cells in vivo : bone marrow-derived cells do not contribute to tumor endotheliumIn: Blood, Jg. 104, 2004, Nr. 6, S. 1769 – 1777
-
The scl +18/19 stem cell enhancer is not required for hematopoiesis : identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1In: Molecular and Cellular Biology (MCB), Jg. 24, 2004, Nr. 5, S. 1870 – 1883
-
Expression pattern of the stem cell leukaemia gene in the CNS of the embryonic and adult mouseIn: Neuroscience, Jg. 122, 2003, Nr. 2, S. 421 – 436
-
The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12In: Proceedings of the National Academy of Sciences of the United States of America (PNAS), Jg. 100, 2003, Nr. 3, S. 992 – 997
-
Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival : an Analysis By the German Study Group for MPN (GSG-MPN)
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 406DOI (Open Access) -
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) : an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 144, 2024, Nr. Supplement 1, S. 1766 – 1766DOI (Open Access)
-
Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations
65th Annual Meeting of the American-Society-of-Hematology (ASH); DEC 09-12, 2023; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 142, 2023, Nr. Supplement 1, S. 747 – 750DOI (Open Access) -
Second-line ponatinib in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment : An interim analysis of the PONS trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 69DOI (Open Access) -
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 1784 – 1787DOI (Open Access) -
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia : an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 1501 – 1503DOI, Online Volltext (Open Access) -
Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex : Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 12194 – 12196DOI (Open Access) -
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia : Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1, S. 1790 – 1793DOI (Open Access) -
Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment : An Interim Analysis of the Prospective PONS Trial
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 12202 – 12203DOI (Open Access) -
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 139 – 141DOI (Open Access) -
Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 4637 – 4640DOI (Open Access) -
Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 138, 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 3608 – 3610DOI (Open Access) -
A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling
61st ASH (American Society of Hematology) Annual Meeting & Exposition; Dec 07 - 10 2019; Orlando, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 134, 2019, Nr. Supplement_1, S. 2537 – 2537DOI (Open Access) -
Clonal evolution in eltrombopag-resistant aplastic anemia indicated by a novel mutation in transcripts of the thrombopoietin-receptor MPL : a case report
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 42, 2019, Nr. Supplement 4: Abstracts, S. 147 – 148DOI (Open Access) -
Updated Results from the German Mpnsg-0212 Combination Trial : Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 134, 2019, Nr. Supplement_1, S. 672 – 672DOI (Open Access) -
Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 4292 – 4292DOI (Open Access) -
Pharmacologic LSD1 Inhibition Preserves Human Granulocytic While Expanding Monocytic Progenitors
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 132, 2018, Nr. Supplement 1, S. 2645 – 2645DOI (Open Access) -
Pharmacologic LSD1 inhibition perturbs human terminal granulopoiesis while preserving monopoiesis
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 77DOI (Open Access) -
Introduction of 2D human leucocyte migration assays suited for the application in the clinical setup
47th Annual Meeting of the German Society for Immunology, 12–15 September, 2017, Erlangen, Germany,In: European Journal of Immunology. Hoboken: Wiley, Jg. 47, 2017, Nr. Suppl. 2: Abstracts of DGfI 2017, S. 232 -
Establishment of a real-time PCR assay to quantify the size of a NOTCH1 mutated subclone in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 60 -
Expansion of a stimulatory natural killer receptor NKp80-expessing CD8+T-cell subset in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 191 -
Inducible depletion of hematopoietic stem cells in vivo challenges niche availability as the critical determinant for bone marrow engraftmentIn: Experimental Hematology. Amsterdam; Oak Ridge, Tenn.; Copenhagen; New York, NY; Berlin; Heidelberg [u.a.]; Charlottesville, Va.: Elsevier, Jg. 41, 2013, S. S42
-
Mice with thymic epithelial deletion of the von Hippel-Lindau gene are lacking a functioning thymusIn: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 276
-
Preclinical testing of a novel CDK9 inhibitor in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 195 – 196 -
Vav-iCre-mediated deletion of the von Hippel-Lindau gene does not alter the cell cycle status of hematopoietic stem cells in vivo
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 292 – 293 -
Heterogeneous Interactions of Leukemic and Control Bone Marrow Stroma Cells with an AML Cell Line and AML Leukemic BlastsIn: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 116, 2010, Nr. 21, S. 460
-
Heterogeneous interactions of leukemic and control bone marrow stroma cells with an AML cell line and AML leukemic blasts
Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Onkologie Jahrestagung, Berlin, Oktober 2010,In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 235 -
Investigating the interaction of leukemic B and non-malignant T cells in a novel Rag2-/gamma c-/--xenograft model of human chronic lymphocytic leukemia (CLL)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 6, S. 202 -
Transkriptionale Regulatoren: Funktionen und Anwendungen in der Hämapotoese und in der Entstehung und Therapie von KrebserkrankungenDuisburg ; Essen, 2018
-
Incidence and prevalence of myelofibrosis (MF) in Germany : a retrospective claims data analysis
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ;13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 274 – 275DOI (Open Access) -
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF) : Updated Results and Genomic Analyses
64th Annual Meeting and Exposition of the American Society of Hematology, December 10 - 13, 2022, New Orleans,In: Blood. Washington; New York, NY [u.a.]; Philadelphia, Pa.: American Society of Hematology, Jg. 140, 2022, Nr. Supplement 1: 64th Annual Meeting, S. 9717 – 9720DOI (Open Access) -
Results from the phase-Ib/II combination trial MPNSG-0212 : Ruxolitinib plus pomalidomide in myelofibrosis with anemia
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 159DOI (Open Access) -
Stammzellenforschung in Essen
Die kleine Form, 05. November 2008, Essen,2008(Die kleine Form 2008/2009)